- Conditions
- End Stage Renal Disease, Infection
- Interventions
- Intravenous antibiotics
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,170
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Intracranial Tumor
- Interventions
- ABY-029
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Influenza
- Interventions
- Pasteurized milk contaminated with killed A(H5) virus
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Diffusing Alpha-emitter Radiation Therapy, Docetaxel, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Modified Barium Swallow Study, Observation Activity, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IV Vaginal Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7, Unresectable Vaginal Carcinoma, Vaginal Adenocarcinoma, Vaginal Adenosquamous Carcinoma, Vaginal Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
- Interventions
- Brachytherapy, Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Radiation Therapy, Triapine
- Radiation · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 377
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 253 more
- Conditions
- Overweight and Obesity
- Interventions
- AMG 133 (frozen liquid), AMG 133 (liquid)
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more
- Conditions
- Anxiety, Cardiovascular Disease
- Interventions
- Lexapro, Placebo, Supervised Aerobic Exercise
- Drug · Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Palatal Donor Site Wound Healing, Platelet Rich Fibrin, Sleep Quality, Pain, Analgesic Consumption
- Interventions
- Platelet rich fibrin, Control Group: collagen matrices or oxidized cellulose membrane
- Procedure · Other
- Lead sponsor
- 59th Medical Wing
- Federal
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Stroke
- Interventions
- Magnesium Chloride, Placebo
- Drug
- Lead sponsor
- Relox Medical, LLC
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Grand Rapids, Michigan • Suffern, New York • Toledo, Ohio
- Conditions
- Hypertension
- Interventions
- Patient educational letter to engage provider in hypertension rx discussion, Financial incentive (Arms B and C) and health educator phone call (Arm C)
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 834 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Minneapolis, Minnesota
- Conditions
- Adverse Drug Reaction
- Interventions
- Pharmacogenetic Intervention Arm (pharmacogenetic testing)
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
- Interventions
- Avelumab, Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 654 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 271
- States / cities
- Phoenix, Arizona • Auburn, California • Berkeley, California + 214 more
- Conditions
- Tolerance
- Interventions
- 1 serving of test product, 2 servings of test product, 3 servings of test product, Placebo
- Other
- Lead sponsor
- Liquid I.V.
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Scabies
- Interventions
- Permethrin Cream, 5%, Elimite
- Drug
- Lead sponsor
- Mayne Pharma International Pty Ltd
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Miami, Florida • Richland, Washington
- Conditions
- Myelodysplastic Syndromes
- Interventions
- FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software
- Drug · Other · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Periodontitis, Periodontal Diseases, Periodontal Pocket
- Interventions
- Amoxicillin, Metronidazole, Placebo
- Drug · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Carcinoma, Transitional Cell
- Interventions
- Rogaratinib (BAY1163877), Chemotherapy
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 16
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 13 more
- Conditions
- Blood Coagulation Test
- Interventions
- GEM Hemochron 100 ACT
- Diagnostic Test
- Lead sponsor
- Accriva Diagnostics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 6 more
- Conditions
- HIV Infections
- Interventions
- In Vitro Diagnostic Device
- Device
- Lead sponsor
- Chembio Diagnostic Systems, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 2,808 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- La Jolla, California • Fort Lauderdale, Florida • Baltimore, Maryland + 2 more
- Conditions
- Long COVID, Insulin Resistance, Insulin Sensitivity
- Interventions
- Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
- Procedure · Diagnostic Test
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Palo Alto, California
- Conditions
- Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia
- Interventions
- ibrutinib, Correlative laboratory samples, quality of life assessment
- Drug · Other
- Lead sponsor
- Kami Maddocks, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer
- Interventions
- F-Var3 PET/CT, Blood draw
- Diagnostic Test · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
- Interventions
- Panzyga, 10% Intravenous Solution, Placebo
- Drug · Other
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Glendale, Arizona • Mesa, Arizona • Scottsdale, Arizona + 3 more
- Conditions
- COVID, Corona Virus Infection, COVID19
- Interventions
- Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo
- Biological · Other
- Lead sponsor
- Joanne Kurtzberg, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more